SVP, Late-Stage Oncology Development & Strategy

Regulatory Jobs; Redwood City (CA); On-site; USD 419,000 - 523,000; Full time

Job summary

Revolution Medicines is seeking a Senior Vice President, Late-Stage Clinical Development. Reporting to the Chief Medical Officer, this leadership role shapes the portfolio from a single approved medicine to a multi-asset, multi-indication late-stage program.

You will define the global development strategy and own registrational and Phase 3 programs across all assets. The role involves coordinating with the Global Development Team Leads, hiring and mentoring leaders, and aligning clinical science

Qualifications

• MD or MD/PhD trained as medical oncologist.
• Substantial late-stage oncology development experience and global regulatory filings.
• Depth in pancreatic, colorectal or lung cancer preferred.
• Track record leading development teams across assets.
• Ability to build and structure a clinical development organization.
• Strong scientific judgment and credibility to guide leaders.
• Effective operating in a fast-moving environment with senior stakeholders.
• Motivated by pipeline impact and changing standard of care.

Responsibilities

• Drive the late-stage development strategy for the RAS(ON) portfolio.
• Own registrational and Phase 3 trials across all programs.
• Shape indication sequencing, study design, endpoints.
• Lead and grow Global Development Team Leads.
• Build a late-stage organization with clear program ownership.
• Partner with regulatory on global filings and lifecycle planning.
• Collaborate on portfolio strategy with Chief Medical Officer and Chief Development Officer.
• Represent the company with clinical collaboration partners.
• Engage investigators and key opinion leaders in trials.

Skills

Medical oncology

Late-stage dev

Regulatory filings

Team leadership

Clinical strategy

Stakeholder alignment

Scientific judgment

Executive leadership

Education

MD or MD/PhD

Job description

Revolution Medicines is seeking a Senior Vice President, Late-Stage Clinical Development. Reporting to the Chief Medical Officer, this leadership role shapes the portfolio from a single approved medicine to a multi-asset, multi-indication late-stage program.

You will define the global development strategy and own registrational and Phase 3 programs across all assets. The role involves coordinating with the Global Development Team Leads, hiring and mentoring leaders, and aligning clinical science